ClinicalTrials.gg
RecruitingNCT05969041MYE SymphonyUpdated Jan 18, 2024

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

A Phase 1 interventional study of MT-302 (A) in Epithelial Tumors, Malignant, sponsored by Myeloid Therapeutics. Recruiting at 6 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Myeloid Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Carcinoma with a site in Australia — 14 open to participants now, 22 under way, 12 of them phase 3. Carcinoma · Australia.

Planned enrollment
42nd of 48
48 · median 263
Started
2023
with 2 others
Phase 1
7 of 48
2 open now
Primary completion
2027-08
later than 9 of 21 live
Registered
38th of 48
by date

Among the 48 studies in Carcinoma with a site in Australia, this one is the 42nd largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 1, reaches primary completion later than 9 of the 21 other live ones, and was the 38th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

14 of the 48 studies in Carcinoma with a site in Australia are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Carcinoma with a site in Australia, or all of them as a file.
02

Study summary

MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.

Read the detailed description

The study has 4 Cohorts. Each Cohort has 4 Cycles. For Cohorts 1-3, the dosing regimen will be every 14 days for 3 doses, followed by administration once every 28 days for three doses. For Cohort 4, the dosing regimen will be modified. Participants will receive one dose of MT-302 every week for 3 doses, followed by administration once every 28 days for three additional doses.

A Safety Review Committee (SRC) will provide oversight for this study. The primary responsibility of the SRC is to safeguard study participants by reviewing and assessing the clinical safety data being collected during the conduct of the study.

03

Conditions studied

  • Epithelial Tumors, Malignant

Keywords

  • Urothelial cancer
  • Cervical cancer
  • Ovarian epithelial
  • Triple-negative breast cancer
  • HR+/HER2- breast cancer
  • Pancreatic ductal adenocarcinoma
  • Gastric adenocarcinoma
  • Esophageal carcinoma
  • Non-small cell lung cancer
  • Colorectal cancer
  • TROP-2 expressing tumors
  • MT-302
  • Anti-TROP-2 chimeric antigen receptor
  • Myeloid cells
  • Monocytes
  • Chimeric Antigen Receptor (CAR)
  • mRNA
  • Lipid nanoparticle (LNP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults age ≥ 18 inclusive at the time the Form (ICF) is signed.
  2. proven, or advanced epithelial cancer including the following cancer types:

    1. Urothelial
    2. Cervical
    3. Ovarian epithelial
    4. Triple-negative breast
    5. HR+/- breast
    6. Pancreatic ductal adenocarcinoma
    7. Gastric adenocarcinoma
    8. Esophageal carcinoma
    9. Non-small cell lung
    10. Colorectal
  3. Progressive disease at baseline, or relapsed to standard of care or who have declined standard therapy.
  4. based on (RECIST) criteria v 1.1.
  5. (ECOG) performance status grade of 0 or 1.
  6. of > 12 weeks.
  7. Echocardiogram (ECHO) or multiple gated acquisition scan showing an greater than or equal to 50%.
  8. (ECG) showing no abnormality at Screening or showing an average \< 450 msec in males and \< 470 msec in females (\< 480 msec for participants with bundle branch block). Either Fridericia's or Bazett's formula may be used to correct the QT interval.
  9. Oxygen saturation of greater than or equal to 90% on room air measured by pulse oximetry.
  10. Adequate organ function as defined by laboratory values at Screening.
  11. Willing and able to provide written informed consent.
  12. Willing to perform and comply with all study procedures including undergoing study-related and attending clinic visits as scheduled.
  13. Men must abstain from sperm donation during study treatment or for 4 months following last dose of study treatment.
  14. Men and must be willing to practice a highly effective method of .

Exclusion criteria

Exclusion Criteria:

  1. Known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging), clinically stable, and without requirement of treatment for at least 14 days prior to the first dose of study intervention.
  2. Pregnant or nursing women.
  3. Must be > 28 days beyond major surgery, including hepatectomy or joint replacement.
  4. Prior bone marrow transplantation or solid organ transplant.
  5. Spinal cord compression not definitively treated with surgery and/or radiation.
  6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
  7. Any acute illness including fever (> 100.4° F or > 38° C) within 7 days prior to Day 1
  8. Active systemic bacterial, fungal, or viral infection within 7 days prior to Day 1. Participant cannot have tested positive for COVID-19 within 7 days prior to Day 1.
  9. Active infection with (HIV), virus (HBV), virus (HCV).
  10. Other primary , except:

    1. Adequately treated basal cell or squamous cell carcinoma
    2. In situ carcinoma of the cervix or bladder, treated curatively and without evidence of recurrence for at least 2 years prior to the study, or
    3. A primary malignancy which has been completely resected and in complete remission for at least 2 years
  11. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  12. Prior grade > 3 immune-related AEs such as pneumonitis, colitis, hepatitis, nephritis; prior dermatitis and endocrinopathies are allowed provided corticosteroids are no longer required and endocrine-replacement therapy is stable and discontinued from prior therapy.
  13. Active disease not related to prior therapy for primary malignancy that has required systemic therapy in the last 1 year.
  14. History of symptomatic congestive heart failure ( classes II-IV) or serious active arrhythmias or other cardiac disease within 12 months of enrollment.
  15. Toxicity from previous anti-cancer therapy defined as toxicities (other than alopecia, or laboratory values listed above) not yet resolved to v5.0 Grade ≤ 1 or baseline. Participants with chronic Grade 2 toxicities (eg, peripheral neuropathy, laboratory values) may be eligible per the discretion of the Investigator and Medical Monitor.
  16. Has received:

    1. Radiotherapy within 2 weeks of first administration of MT-302
    2. Cytotoxic chemotherapy for treatment of the primary malignancy within 28 days or 5 half-lives, whichever is shorter, of administration of MT-302
    3. Immune therapy for primary malignancy (eg, monoclonal antibody therapy, ) within 28 days or 5 half-lives, whichever is shorter of first administration of MT-302
    4. Targeted therapies for primary malignancy within 28 days or 5 half-lives, whichever is shorter, of first administration of MT-302
    5. Anti-cancer vaccine within 12 weeks of first administration of MT-302
    6. COVID-19 mRNA vaccine within 6 weeks of first administration of MT-302
  17. Has received a ≤ 6 weeks prior to first administration of MT-302
  18. Has received packed red blood cells or transfusion within 2 weeks prior to first administration of MT-302
  19. History of an allergic reaction to any of the
  20. Enrollment in another interventional clinical trial within 28 days or 5 half-lives of the drug, whichever is shorter, of first administration of MT-302
  21. Any other condition that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the study requirements.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    A (MT-302)

    Participants will receive MT-302 through intravenous infusion.

    Drug: MT-302 (A)

Interventions

  • DrugMT-302 (A)

    MT-302 is an investigational drug

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of MT-302 through incidence of Adverse Events

    Adverse Events will be graded according to the NCI-CTCAE, version 5.0

    Time frame: Up to Week 20

  2. To establish the maximum tolerated dose (MTD)

    based on dose limiting toxicities (DLTs) and the recommended Phase 2 dose (RP2D)

    Time frame: Up to Week 20

Secondary outcomes

  1. To further characterize the safety of MT-302 through incidence of Adverse Events

    Adverse Events will be graded according to the NCI-CTCAE, version 5.0

    Time frame: Up to Week 20

  2. To assess the pharmacokinetics (PK) of MT-302

    PK parameter: Plasma concentrations

    Time frame: Up to Week 20

  3. To assess the pharmacokinetics (PK) of MT-302

    PK parameter: Area under curve (AUC0-last, AUC 0-∞)

    Time frame: Up to Week 20

  4. To assess the pharmacokinetics (PK) of MT-302

    PK parameter: Time of maximum observed plasma concentration (tmax)

    Time frame: Up to Week 20

  5. To assess the pharmacokinetics (PK) of MT-302

    PK parameter: Apparent terminal Half-life (t1/2)

    Time frame: Up to Week 20

  6. To assess the pharmacokinetics (PK) of MT-302

    PK parameter: Plasma Clearance (CL)

    Time frame: Up to Week 20

  7. To assess the pharmacokinetics (PK) of MT-302

    PK parameter: Volume of Distribution (Vd)

    Time frame: Up to Week 20

  8. To assess the pharmacokinetics (PK) of MT-302

    PK parameter:Mean residence time (MRT)

    Time frame: Up to Week 20

  9. To assess the pharmacokinetics (PK) of MT-302

    PK parameter: terminal rate constant ( λz)

    Time frame: Up to Week 20

  10. Determine rate of ICANS

    For grading of potential immune effector cell-associated neurotoxicity syndrome (ICANS), use of the 10-point immune effector cell-associated encephalopathy (ICE) screening tool

    Time frame: Up to Week 20

  11. Determine rate of Grade 3-5 CRS

    ASCO CRS Grading

    Time frame: Up to Week 20

07

Study locations

6 of 6 sites recruiting
  • St Vincent's Public Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
    • Rasha Cosman, MD · Contact
  • Scientia Clinical Research Ltd
    Randwick, New South Wales 2031, Australia
    Recruiting
    • Charlotte Lemech, MD · Contact
    • Charlotte Lemech, MD · Principal investigator
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Adnan Nagrial · Contact
    • Adnan Nagrial, MD · Principal investigator
  • Souther Oncology Clinical Research Unit (SOCRU)
    Bedford Park, South Australia 5042, Australia
    Recruiting
    • Ganessan Kichendasse, MD · Contact
  • Cabrini Health
    Malvern, Victoria 3144, Australia
    Recruiting
    • Gary Richardson, MD · Contact0395089542
    • Gary Richardson, MD · Principal investigator
  • Linear Clinical Research Ltd
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Timothy Humphries, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 48 months after the start.

Of 42 industry-sponsored phase 1 interventional studies under Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's planned 48 months is above that.

Counting every sponsor, half of 71 studies reached it within 46 months; a quarter within 30 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Aug 1, 2023
StartActual
Aug 2, 2023
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05969041
Lead sponsor
Myeloid Therapeutics
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 2, 2023
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jan 18, 2024

Study contacts

Shinam Garg
Contact
Shinam.garg@novotech-cro.com
+61 2 9171 3260
Clinical Operations
Contact
mt-302clinical@myeloidtx.com
+1 617 465 1022
Matthew Maurer, MD
study director · Myeloid Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion